The Impact of Whey Protein on Frailty in Older Adults Classified as Pre-frail
- Conditions
- Pre-frailPre-Frail Older AdultsCognitionPhysical FunctionDietary Intake AssessmentMRI
- Registration Number
- NCT07167277
- Lead Sponsor
- University of Kansas Medical Center
- Brief Summary
This pilot study aims to determine the impact of whey protein supplementation on brain antioxidant levels and to assess the effects of whey protein supplementation on physical function, body composition, and cognition in pre-frail older adults.
- Detailed Description
Frailty is characterized by weakness, muscle loss, and physical impairment. It is suggested that long term oxidative stress might contribute to frailty. Glutathione (GSH), an antioxidant in cells, is needed to combat oxidative stress. Whey protein has the potential to increase brain antioxidant (GSH) levels by aiding in antioxidant synthesis. Frail older adults under-consume protein compared to healthy older adults.
Researchers want to see if supplementing with whey protein will improve brain antioxidant status in pre-frail older adults. They will measure this by using special Magnetic Resonance Imaging (MRI) scans.
Participants will be asked to complete a total of 4 study visits, all taking place on the University of Kansas Medical Center (KUMC) main campus. Two of these visits will include an MRI scan. Participation will last about 3 months.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Pre-frail according to Fried's phenotype
- Age 65 to 85
- Speak English as primary language and able to read and write in English
- Stable medication for ≥ 30 days
- Not already taking whey protein over the past 30 days
- Acute or chronic kidney disease
- Recent major health concerns
- Insulin-requiring diabetes
- Cancer requiring chemotherapy or radiation within the past 5 years
- Cardiac event (i.e., MI, etc.) in the past year
- Dementia or neurodegenerative disease
- Clinical trial or investigational drug or therapy participation within 30 days of the screening visit or during enrollment in the current study
- MRI contraindications (pacemaker, aneurysm clips, artificial heart valves, metal fragments, foreign objects or claustrophobia)
- Dairy Allergy or excluding dairy from diet for other reasons
- Weight > 350 lbs.
- The presence of major psychiatric disorders within the past 3 years including depression, anxiety, and alcohol (over 3 drinks/day or a total of 18 drinks/week) or drug abuse.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in brain glutathione (GSH) levels measured using MRI scans. Changes from baseline to 3 months. Brain GSH levels will be measured using 3T MRI scans.
- Secondary Outcome Measures
Name Time Method Assess the change in physical function by measuring balance resistance, sit-to-stand, muscle strength and performance. Changes from baseline to 3 months. Balance resistance will be measured with a pressure-sensitive walkway. Sit-to-stand will be measured by number of repetitions in 30 seconds and the time to complete 5 repetitions. Muscle strength and performance will be measured by grip strength and gait speed. Grip strength is measured 3 times and averaged. Gait speed is measured with a 15-foot walk test and will be measured twice.
Assess body composition with a bioelectrical impedance analysis (BIA) device. Changes from baseline to 3 months. To measure, subjects will stand on the device, covering the electrodes with their hands and feet. The measure takes less than 2 minutes.
Assess cognition using the NIH Toolbox cognition battery. Changes from baseline to 3 months. The NIH Toolbox cognition battery will include 5 tests resulting in a composite score. The exam will be administered on an iPad device.
Trial Locations
- Locations (1)
The University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States
The University of Kansas Medical Center🇺🇸Kansas City, Kansas, United States